The ABCs of Assessing Cognition in Oncology Clinical Trials: Applications, Benefits, and Considerations, New Webinar Hosted by Xtalks

TORONTO, ON--(Marketwired - May 01, 2017) - In a live presentation, industry expert Dr. Jeffrey Wefel, Section Chief and Associate Professor, Section of Neuropsychology, Department of Neuro-Oncology at The University of Texas MD Anderson Cancer Center will discuss the role and relevance of cognitive endpoints in clinical trials to accelerate our understanding of cognitive dysfunction related to cancer and cancer treatments.

Nearly all patients with central nervous system (CNS) and many patients with non-CNS cancers experience cognitive problems during their disease and treatment that can result in diminished quality of life and functional independence. While overall survival and progression-free survival have been the most widely accepted clinical trial endpoints in evaluating oncology therapies, more recently, there has been a growing interest in patient-centered clinical outcome assessments (COAs) that measure the impact of disease and treatments on an individual's overall functioning, including cognitive function.

By attending this webinar, participants will be able to:

• Define neurocognitive deficits in patients with cancer
• Discuss the impact of cognitive dysfunction on the life of patients with cancer
• Describe approaches to the assessment of cognition in clinical trials including key considerations for selecting appropriate and acceptable measures, implementing cognitive outcomes, and outcome positioning
• Describe differences between performance-based outcomes and patient reported outcomes as well as regulatory perspectives on each
• Discuss case examples from studies of brain tumors, brain metastasis and non-CNS cancers

Join Dr. Jeffrey Wefel on Tuesday, May 16, 2017 at 11am EDT (4pm BST/UK). For more information or to register for this complimentary event sponsored by Cogstate Ltd, visit: The ABCs of Assessing Cognition in Oncology Clinical Trials: Applications, Benefits, and Considerations

About Cogstate
Cogstate Ltd (ASX: CGS) is a leading cognitive science company dedicated to optimizing the measurement of cognition in clinical trials, academic research and healthcare. Cogstate provides expert support and eCOA for neuropsychological and functional assessments and is a pioneer in commercializing rapid, reliable and highly sensitive computerised cognitive tests. Cogstate customers include the world's leading biopharmaceutical companies; military and elite sporting organizations; physicians and patients; renowned academic institutions and public-private partnerships. For more information visit www.cogstate.com.

About Xtalks
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/sponsorship.ashx

Image Available: http://www.marketwire.com/library/MwGo/2017/4/27/11G137216/Images/Cogstate_Logo-6611b8c126c8b8f4ac31fbd113d2af7e.jpg